. Author manuscript; available in PMC: 2018 Apr 11.

Published in final edited form as: N Engl J Med. 2017 Jan 12;376(2):125–135. doi: 10.1056/NEJMoa1607427

Table 3. Overview of Adverse Events (Safety Population)^*.

Event	¹⁷⁷Lu-Dotatate Group (N = 111)	Control Group (N = 110)	P Value^†
	number of patients (percent)

Adverse event

Any	106 (95)	95 (86)	0.02
Related to treatment	95 (86)	34 (31)	<0.001

Serious adverse event

Any	29 (26)	26 (24)	0.76
Related to treatment	10 (9)	1 (1)	0.01

Withdrawal from trial because of adverse event

Because of any adverse event	7 (6)	10 (9)	0.46
Because of adverse event related to treatment	5 (5)	0	0.06

The safety population included all patients who underwent randomization and received at least one dose of trial treatment.

^†

P values were calculated with the use of Fisher's exact text.

Table 3. Overview of Adverse Events (Safety Population)*.